Dr. Steven J. Hatfill, a biosecurity expert hired by HHS Secretary Robert F. Kennedy Jr., has been fired. He was a skeptic of ...
(NASDAQ:MRNA) today announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
Cambridge: Moderna, Inc. has announced topline results from a Phase 3 pivotal trial evaluating the efficacy of mRNA-1647, the ...
Moderna ends its CMV vaccine program after a Phase 3 trial failed to meet efficacy goals, but maintains its 2028 breakeven ...
The recall election is an electoral obligation for those wishing to return representative government back to the resident ...
Topline results were announced from a phase 3 study evaluating Moderna’s cytomegalovirus vaccine candidate, mRNA-1647.
The vaccine, known as mRNA-1647, showed disappointing efficacy against primary CMV infection in healthy women, ranging from ...
Live Science on MSN
'This is a completely different level of anti-vaccine engagement than we've ever seen before,' says epidemiologist Dr. Seth Berkley
Epidemiologist Dr. Seth Berkley spoke to Live Science about the importance of vaccine equity and the obstacles undermining it ...
An ex-firefighter with ties to RFK Jr. is leading the federal agency that handles public health crises and maintains the ...
A study presented at the annual European Society of Medical Oncology Congress 2025 and published in the journal Annals of ...
This insightful review explores key areas of cancer genetic research, focusing on genes that may benefit from ...
Stocktwits on MSN
Moderna Stock Slides After-Hours On CMV Vaccine Failure In Phase 3 Trial — Retail Traders Warn Of ‘Endless’ Cash Burn
Moderna said its cytomegalovirus (CMV) vaccine, mRNA-1647, failed to prevent infection in women of childbearing age in a ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback